Last reviewed · How we verify

Afstyla® — Competitive Intelligence Brief

Afstyla® (Afstyla®) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant clotting factor VIII. Area: Hematology.

marketed Recombinant clotting factor VIII Factor VIII (coagulation factor VIII) Hematology Biologic Live · refreshed every 30 min

Target snapshot

Afstyla® (Afstyla®) — CSL Behring. Afstyla is a recombinant antithrombin III-free factor VIII that replaces deficient clotting factor VIII to restore hemostasis in patients with hemophilia A.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Afstyla® TARGET Afstyla® CSL Behring marketed Recombinant clotting factor VIII Factor VIII (coagulation factor VIII)
rVIII-SingleChain rVIII-SingleChain CSL Behring phase 3 Recombinant clotting factor VIII Factor VIII (coagulation factor VIII)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant clotting factor VIII class)

  1. CSL Behring · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Afstyla® — Competitive Intelligence Brief. https://druglandscape.com/ci/afstyla. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: